{
    "clinical_study": {
        "@rank": "117800", 
        "arm_group": [
            {
                "arm_group_label": "Treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the investigation is to determine whether Atrovastatin as anti-inflammatory\n      agent can be effective in preventing from atrial fibrillation incidence in patients whom\n      undergone open cardiac surgery for their heart valve repair."
        }, 
        "brief_title": "Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Heart Valve Diseases", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Heart Valve Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Greater than 25 y/o\n\n          -  No occurrence of intra- or post-operative cardiopulmonary arrest\n\n          -  Not consuming drugs affecting atrial rhythm\n\n          -  Having sinus rhythm before surgery\n\n          -  Lack of paroxysmal atrial fibrillation history\n\n          -  Only undergo heart valve surgery\n\n          -  Lack of considerable heart ischemia needed atorvastatin use\n\n          -  Routine cares in ward, post-operative ward, and intensive care unit were done\n\n        Exclusion Criteria:\n\n          -  Lesser than 25 y/o\n\n          -  History of atrial fibrillation\n\n          -  History of taking anti-arrhythmic drugs\n\n          -  History of implementing pacemakers\n\n          -  Severe heart failure\n\n          -  Renal failure\n\n          -  Hepatic failure\n\n          -  Severe pulmonary diseases\n\n          -  Heart block or bradyarrhythmia\n\n          -  Routine cares in ward, post-operative ward, and intensive care unit were not  done\n\n          -  Performing concomitant cardiac surgery except valve repair\n\n          -  Having considerable heart ischemia needed atorvastatin use"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084069", 
            "org_study_id": "UMSU-Cardiology-2"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "intervention_name": "Atorvastatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "link": {
            "url": "http://umsu.ac.ir"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Urmia", 
                    "country": "Iran, Islamic Republic of", 
                    "state": "West-Azerbaijan"
                }, 
                "name": "Seyyed-al-Shohada Heart Center"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Atrial fibrillation incidence after open cardiac valve repair", 
            "safety_issue": "Yes", 
            "time_frame": "Within 5 days after open cardiac valve repair"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084069"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Urmia University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Urmia University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}